Amal Therapeutics
Key Facts
| Invested since | 2014 |
| Based in | International |
About the company
Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic cargo.
Do you want to
know more about this company?
Amal Therapeutics in the news
Zum Artikel
Amal Therapeutics raises CHF 3 million in a Series A financing round led by Boehringer Ingelheim Venture Fund
Zum Artikel
Amal Therapeutics SA raises seed round from Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds to develop therapeutic cancer vaccines based on its proprietary technology platform
More startups from Life Sciences
Semi-Exit
Photonics Healthcare enables doctors to monitor cellular oxygen.
To the complete profileof Photonics Healthcare
Hamburg-based COLIPI is developing an industrial biotechnological process that transforms climate-damaging CO2 and carbon-containing industrial waste into Climate Oil. This product serves as a sustainable and climate-neutral alternative to palm …
To the complete profileof COLIPI
Exit
Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat Problem: Solid cancers are still very difficult to treat. Most treatments …
To the complete profileof Emergence Therapeutics
Exit
LOEWI GmbH is a scientific spin-off of the TU München with the mission to make personalized health and nutrition available to everyone by combining science and technology. LOEWI’s patented personalization …
To the complete profileof LOEWI
Exit
lino Biotech AG was incorporated as a ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several lifescience family …
To the complete profileof Lino Biotech
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …
To the complete profileof Lindis Blood Care
Exit
MYR, acquired by Gilead Sciences in 2021, developed a peptide-based, first-in-class drug to combat chronic hepatitis B and delta. The drug has been approved by the EMA for the treatment …
To the complete profileof MYR
Skinuvita is a digital care model for the home use of phototherapy for chronic skin conditions such as psoriasis and neurodermatitis. With the innovative telemedicine system, the prescribed dose is …
To the complete profileof Skinuvita
FundaMental Pharma GmbH (FMP) is developing new types of drugs that act as ‘molecular spacers’ and disrupt a death signaling complex in the brain. Using this pharmacological strategy, FMP scientists …
To the complete profileof FundaMental Pharma
Exit
ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.
To the complete profileof ChromoTek
Hypros (formerly GWA Hygiene) offers innovative digital solutions for the healthcare sector. The focus is on relieving the burden on hospital staff and increasing patient safety. The company, which has …
To the complete profileof Hypros
heartbeat ONE provides a streamlined patient management tool for health care facilities of all sizes. It offers intelligent evaluations of diagnostics and treatment methods. It supports the preparation, documentation and …
To the complete profileof heartbeat medical